219 related articles for article (PubMed ID: 30232698)
1. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Fu J; Liu Y; Lin H; Wu B
Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia.
Agrawal R; Vieira J; Ryan J; Negi H; Rajput T; Corbin R; Viana R
Pharmacoeconomics; 2022 Dec; 40(12):1159-1186. PubMed ID: 36175789
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
Wu B; Liu M; Li T; Lin H; Zhong H
Medicine (Baltimore); 2017 Jul; 96(29):e7445. PubMed ID: 28723754
[TBL] [Abstract][Full Text] [Related]
11. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
14. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
15. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
Kenzik KM; Bhatia R; Bhatia S
JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
Elias F; Gebran A; Said C; Beker RV; Ammar W
J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826
[TBL] [Abstract][Full Text] [Related]
18. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Jabbour EJ; Mendiola MF; Lingohr-Smith M; Lin J; Makenbaeva D
J Med Econ; 2019 Nov; 22(11):1113-1118. PubMed ID: 31074658
[No Abstract] [Full Text] [Related]
19. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]